



## Efficacy Summary

Establishment Name	Example Vaccines, Inc.
Establishment Number	Est. Lic. No. ###
Study Identifier	<b>2XY</b>
Test Product True Name	Virus2-Virus4-Virus 6
Test Product VS Code	1123.xx
<b>Study Design</b>	
Number of Doses, Route & Timing of Administration	Info here
Number of animals/group, Type of animals and age at first vaccination/treatment	Texts & Data
<b>Challenge Data</b>	
Challenge description	Texts & Data
<b>Primary Outcome</b>	Texts & Data.
<b>Efficacy Outcome/Results</b>	Texts & Data.
# Animals Protected: Group A (IM vaccinate) Group B (SQ vaccinates) Group C (Controls)	Texts & Data
Lung Lesions: Visual observation and palpation	Texts & Data
Clinical Scores: 0 =Normal (no significant clinical signs) 1 = Moderate (coughing and/or increased respiration) 2 = Severe (clinical pneumonia, labored breathing and/or severe cough)	Texts & Data

**APPROVED**

## Efficacy Summary

Establishment Name	Example Vaccines, Inc.
Establishment Number	Est. Lic. No. ###
Study Identifier	<b>3AAA</b>
Test Product True Name	Bacteria-Bacteria-Bacterin
Test Product VS Code	2001.xx
<b>Study Design</b>	
Number of Doses, Route & Timing of Administration	Info here
Number of animals/group, Type of animals and age at first vaccination/treatment	Texts & Data
<b>Challenge Data</b>	
Challenge description	Texts & Data
<b>Primary Outcome</b>	Texts & Data.
<b>Efficacy Outcome/Results</b>	Texts & Data.
# Animals Protected: Group A (IM vaccinate) Group B (SQ vaccinates) Group C (Controls)	Texts & Data
Lung Lesions: Visual observation and palpation	Texts & Data
Clinical Scores: 0 =Normal (no significant clinical signs) 1 = Moderate (coughing and/or increased respiration) 2 = Severe (clinical pneumonia, labored breathing and/or severe cough)	Texts & Data

**APPROVED**

## Efficacy Summary

Company Name	Example Vaccines, Inc.
Establishment Number	Est. Lic. No. ###
Study Identifier	<b>No. 1</b>
Test Product True Name	Virus2-Virus4-Virus 6, Killed Virus-Haemophilus Parasuis-Bacteria 2-Bacteria-3 Bacterin
Test Product VS Code	1112.xx
<b>Study Design</b>	
Number of Doses, Route & Timing of Administration	Info here
Number of animals/group, Type of animals and age at first vaccination/treatment	Texts & Data
<b>Challenge Data</b>	
Challenge description	Texts & Data
<b>Primary Outcome</b>	Texts & Data.
<b>Efficacy Outcome/Results</b>	Texts & Data.
# Animals Protected: Group A (IM vaccinate) Group B (SQ vaccinates) Group C (Controls)	Texts & Data
Lung Lesions: Visual observation and palpation	Texts & Data
Clinical Scores: 0 =Normal (no significant clinical signs) 1 = Moderate (coughing and/or increased respiration) 2 = Severe (clinical pneumonia, labored breathing and/or severe cough)	Texts & Data

**APPROVED**

## Licensing Safety Summary

Establishment Name	Example Vaccines, Inc.										
Establishment Number	Est. Lic. No. ###										
Study Identifier	<b>JKL-MN-OPQR</b>										
Test Product True Name	Virus2-Virus4-Virus 6, Killed Virus-Haemophilus Parasuis-Bacteria 2-Bacteria-3 Bacterin										
Test Product VS Code	1112.xx										
<b>Study Design</b>											
Number of Doses, Route & Timing of Administration	Info here										
Number of animals/group, Type of animals and age at first vaccination/treatment	Info here										
<b>Safety Study Outcome/Results</b>											
Number of animals exhibiting adverse events associated with vaccination.											
Animals: Group A (IM vaccinate; 50 pigs each route) Group B (SQ vaccinates; 50 pigs each route) Group C (Controls; 50 pigs each route)			<b>IM Vaccinates</b>		<b>SC Vaccinates</b>		<b>Controls</b>				
			<b>3-4wk</b>		<b>&gt;4wk</b>		<b>3-4wk</b>		<b>&gt;4wk</b>		
			<b>Adverse Event</b>								
Injection Site Swelling	0		0		7		11		0		
Respiratory Distress	0		0		0		1*		0		
Anaphylaxis	0		0		0		0		0		
Cough	0		0		0		0		0		
Pain	1		0		2		1		1		
Vocalization	0		0		0		0		0		
Lameness	0		0		0		0		0		
Abcess	0		0		0		0		0		
Bloating	0		0		0		0		0		
Recumbent	0		0		0		0		0		
Death	0		0		0		0		0		
No adverse Reaction	49		50		41		37		49		
Results represent the total number of adverse events after any vaccination.											
An asterisk (*) denotes adverse events occurring after the second vaccination.											

APPROVED